183 related articles for article (PubMed ID: 35979276)
1. Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report.
Kiraly P; Groznik AL; Valentinčič NV; Mekjavić PJ; Urbančič M; Ocvirk J; Mesti T
World J Clin Cases; 2022 Jul; 10(19):6536-6542. PubMed ID: 35979276
[TBL] [Abstract][Full Text] [Related]
2. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.
Draganova D; Kerger J; Caspers L; Willermain F
J Ophthalmic Inflamm Infect; 2015; 5():17. PubMed ID: 26078801
[TBL] [Abstract][Full Text] [Related]
3. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
4. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib.
Rueda-Rueda T; Sánchez-Vicente JL; Moruno-Rodríguez A; Molina-Socola FE; Martínez-Borrego AC; López-Herrero F
Arch Soc Esp Oftalmol (Engl Ed); 2018 Sep; 93(9):458-462. PubMed ID: 29580759
[TBL] [Abstract][Full Text] [Related]
5. VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report.
Gunaratnam C; Muzicenco O; Sivagurunathan P; Franzco MH
J Surg Case Rep; 2024 Mar; 2024(3):rjae104. PubMed ID: 38455982
[TBL] [Abstract][Full Text] [Related]
6. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
7. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
8. Trametinib: a MEK inhibitor for management of metastatic melanoma.
Lugowska I; Koseła-Paterczyk H; Kozak K; Rutkowski P
Onco Targets Ther; 2015; 8():2251-9. PubMed ID: 26347206
[TBL] [Abstract][Full Text] [Related]
9. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
10. Ocular toxicity due to Trametinib and Dabrafenib.
Sarny S; Neumayer M; Kofler J; El-Shabrawi Y
BMC Ophthalmol; 2017 Aug; 17(1):146. PubMed ID: 28818062
[TBL] [Abstract][Full Text] [Related]
11. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
[TBL] [Abstract][Full Text] [Related]
12. A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma.
Yanagihara RT; Tom ES; Seitzman GD; Saraf SS
Ocul Immunol Inflamm; 2022; 30(7-8):2005-2009. PubMed ID: 34009099
[TBL] [Abstract][Full Text] [Related]
13. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
18. New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.
Luke JJ; Ott PA
Drug Healthc Patient Saf; 2014; 6():77-88. PubMed ID: 25018652
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Steroid Treatment for Uveitis Associated with Dabrafenib and Trametinib for Metastatic Cutaneous Melanoma.
Woltsche N; Kruger MA; Weger M; Wolf IH; Seidel G
Ocul Immunol Inflamm; 2021 Jul; 29(5):845-847. PubMed ID: 31906779
[No Abstract] [Full Text] [Related]
20. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
